Monthly Archives: June 2020

The NGK blockchain will be launched in the world through STO, and the super community will be launched soon!

NEW YORK, NY / ACCESSWIRE / June 29, 2020 / The first issue of NGK blockchain application for digital currency STO has attracted widespread attention. This time STO won the STO digital financing certificate issued by the trust agency and the SEC (United States Securities and Exchange Commission), which will be held by the founding company USA International Covenant INC. As the background of STO currency issuance, and the NGK.IO blockchain successfully applied for the US MSB blockchain license, NGK plans to officially release the white paper 2.0 in August 2020 and go online in October 2020.

Related introduction:

USA International Covenant INC acquired Spirit Stone's blockchain technology department in 2018, and began research and development of the NGK.IO blockchain in June 2018. Spirit Stone designed NGK.IO as a commercial and financial block chain, allowing economic equity certificates On-chain issuance, the users can use the NGK.IO blockchain to issue tokens and equity, and NGK.IO will create a new digital economic ecology to provide enterprises and individuals with the value of equity issuance. Through the decentralized structure, let the real economy connect the blockchain to create decentralized applications. The NGK.IO blockchain realizes the direct conversion of economic value, so that all digital currency enthusiasts can participate in the ecology.

NGK.IO is a blockchain based on the underlying technology of the block chain. It will provide an open network for everyone to choose freely. The construction of the underlying technology of the blockchain will give all transactions on the chain powerful transaction throughput and security. In the storage environment, in the ecology of NGK.IO, all communicative developers and communicative enthusiasts can effectively participate in the blockchain construction system.

NGK.IO is a digital financial management system developed through blockchain technology, through the optimization of the underlying technology and the upgrade of scripts to create a new blockchain business system, continuous and effective optimization of the consensus mechanism, transaction speed, smart contracts The expansion of various functions and the expansion of various functions to improve the speed and security of the overall data architecture, promote the innovation of the global digital asset financial investment industry, become a comprehensive business application platform, and launch traditional financial derivatives into the digital economy to create plans for capital The economic and commercial economy and personal assets and rights provide digital circulation and listing, and NGK.IO will escort the digital economy in all aspects.

NGK Digital Coin will become a bridge of the NGK.IO block chain, used to encourage builders, participants, developers, users in the ecosystem, as well as various commercial applications, property rights management, payment transactions, proof of rights, etc. NGK.IO will continue to promote the technical and application level, complete the commercial process of blockchain digital applications, and lead the new global payment model!

Media Contact

Company Name:NGK

Arthur Wang

Phone:+19175939192

Arthurking7337@gmail.com

SOURCE: NGK

ReleaseID: 595559

GlobeX Data Acquires Sekur.com for Its Anti-Phishing Secure Email and Encrypted Messaging Solution

TORONTO, ONTARIO / ACCESSWIRE / June 29, 2020 / GlobeX Data Ltd. (OTCQB:SWISF)(CSE:SWIS) ("GlobeX" or the "Company"), the leader in Swiss hosted cyber security and Internet privacy solutions for secure data management and secure communications, is pleased to announce that it has successfully acquired the domain Sekur.com through its domain broker Webnames.ca for a total of USD 13,000, including broker fees, negotiated down from a price of USD 18,000 including broker fees. The Company already owns Sekur.ch and has been trying to acquire Sekur.com for the past 6 months.

Sekur is the Company's Swiss hosted secure communications suite, which includes encrypted messaging with self-destruct timer powered by the Company's proprietary PrivaTalk platform and an encrypted email service powered by the Company's Custodia platform. The Company plans to push the Sekur brand as a secure communications suite in addition to its existing DigitalSafe brand which is the Company's document management and collaboration suite. The Company plans to offer Sekur in July 2020 for an introductory price of USD 9.99/user/month or USD 99.90/user/year and will include 100GB of email and message storage.

The service will include the Company's proprietary SecureSend and SecureReply anti-phishing encrypted email solution. SecureSend lets a user send an email to any other recipient, whether they have Sekur or not, in full privacy and security as the email never leaves Sekur's encrypted email servers based in Switzerland. The recipient can then click on the notification and reply in the same manner using SecureReply, without the recipient having to purchase Sekur. This is also a guarantee to eliminate BEC attacks for businesses and email phishing attacks. Additionally, Sekur will include the Company's latest technology improvements made on its Custodia email platform, which include full control of email delivery, data export for SMB and large enterprises and an automatic Data Loss Prevention technology ("DLP") with real time continuous archiving. These technologies are very much in demand from financial institutions and larger enterprises.

One of the many privacy and security features of Sekur is that the user does not register with their phone number, eliminating a huge loophole in security and privacy. Just recently, according to an article written by Lindsey O'Donnell and posted on the website threatpost.com on June 5 2020, it was disclosed that WhatsApp phone numbers and users were searchable on Google, creating a massive security and privacy breach. Earlier in the year, an article was written about a similar flaw affecting all businesses, NGOs, UN and non-profit organizations, where WhatsApp Group members were also compromised and searchable in a reverse engineering trick done on Google.

Recent data breaches in messaging applications and in particular in the WhatsApp application have created a certain urgency for businesses to protect their communications form cyber-attacks and identity theft via mobile devices.

Sekur eliminates many of the privacy and security risks by not only not requiring a phone number, which would divulge a user's phone device ID, but also by not social engineering a user's phone or computer contact list and infecting the contacts by default as well. Sekur issues each user a username and a PTM number. The PTM number is the contact ID a user would disclose in order for other PTM users to be added. The service comes with a self-destruct timer and other features as well, including GlobeX's proprietary VirtualVaults and HeliX technologies with all data stored in Swiss hosted encrypted servers.

GlobeX Data plans to offer Sekur as a secure and private alternative mostly for business users, however, consumers are also in search of more private and secure email and messaging solutions in light of all the cyber-attacks that are increasing due to WFH trends. The Company has already received interest from its partner America Movil, and plans to offer Sekur to all its global partners, starting August 2020. The service will be available for purchase by the end of July 2020 at https://www.sekur.com.

GlobeX's Data privacy solutions are all hosted in Switzerland, protecting users' data from any outside data intrusion requests. In Switzerland, the right to privacy is guaranteed in article 13 of the Swiss Federal Constitution. The Federal Act on Data Protection ("FADP") of 19 June 1992 (in force since 1993) has set up a strict protection of privacy by prohibiting virtually any processing of personal data which is not expressly authorized by the data subjects. The protection is subject to the authority of the Federal Data Protection and Information Commissioner.

Under Swiss federal law, it is a crime to publish information based on leaked "secret official discussions." In 2010 the Federal Supreme Court of Switzerland found that IP addresses are personal information and that under Swiss privacy laws they may not be used to track Internet usage without the knowledge of the individuals involved.

About GlobeX Data Ltd.
GlobeX Data Ltd. is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure data management and secure communications. The Company distributes a suite of secure cloud-based storage, disaster recovery, document management, encrypted e-mails, and secure communication tools. GlobeX Data Ltd. sells its products through its approved wholesalers and distributors, and telecommunications companies worldwide. GlobeX Data Ltd. serves consumers, businesses and governments worldwide.

On behalf of Management

GLOBEX DATA LTD.

Alain Ghiai
President and Chief Executive Officer
+1.416.644.8690
corporate@globexdatagroup.com

For more information please contact GlobeX Data at corporate@globexdatagroup.com or visit us at https://globexdatagroup.com.
For more information on Sekur visit us at: https://www.sekur.com.
For more information on DigitalSafe visit us at: https://digitalsafe.com.

Forward Looking Information
This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws ("forward-looking statements"). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "project" and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions "may" or "will" occur. These statements are only predictions. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guaranteeing future performance. GlobeX cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond GlobeX's control. Such factors include, among other things: risks and uncertainties relating to the future of the Company's business; the success of marketing and sales efforts of the Company; the projections prepared in house and projections delivered by channel partners; the Company's ability to complete the necessary software updates; increases in sales as a result of investments software development technology; consumer interest in the Products; future sales plans and strategies; reliance on large channel partners and expectations of renewals to ongoing agreements with these partners; anticipated events and trends; the economy and other future conditions; and other risks and uncertainties, including those described in GlobeX's prospectus dated May 8, 2019 filed with the Canadian Securities Administrators and available on www.sedar.com. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, GlobeX undertakes no obligation to publicly update or revise forward-looking information.

SOURCE: GlobeX Data Ltd.

ReleaseID: 595516

Halberd Method for Treating and Curing the COVID-19 Infection Explained

JACKSON CENTER, PA / ACCESSWIRE / June 29, 2020 / Halberd Corporation (OTC PINK:HALB) today unveils the first of three (3) COVID -19 (Coronavirus) patent pending treatment methods – the first titled, "Method for Treating and Curing Covid-19 Infection" – filed with the U.S. Patent and Trademark Office on March 16, 2020. Halberd holds exclusive worldwide license to this technology.

The method applicable to any disease entails the extracorporeal (outside the body) treatment of a patient's blood or cerebrospinal fluid (CSF) consisting of a three-step process:

Removal of the bodily fluid from the patient;
Introduction of one or more antibody-antigen complexing agents to bind with the target disease antigen(s) (i.e., coronavirus associated antigen(s)) and removal of the antibody-antigen complex by any number of available methods (mechanical, chemical, or molecular filtering; dialysis; molecular adsorbent recirculating system (MARS); plasmapheresis, etc.) alone, or in combination;
Return of the cleansed bodily fluid to the patient.

This process is intended to be performed during a continuous flow process, similar to normal dialysis. By treating the blood or CSF outside of the patient's body, and using complexing agents which combine only with antigens associated with the targeted disease, negative side-effects and reactions are greatly reduced or eliminated.

Dr. Mitchell S. Felder, inventor of this treatment process, stated, "By treating the bodily fluid outside of the body, we should be able to monitor the appropriate dosing levels of the complexing agent(s) to adjust to the intensity of the disease on a patient-by-patient basis. The goal is to remove all, or at least a sufficient quantity, of the coronavirus antigen load from the body to allow the patient to recover quickly. Once afflicted," Dr. Felder continued, "for many patients, we believe that this may be the only solution. In many cases, for those severely infected, it may too late for a vaccine."

Mr. William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "We see a tremendous potential in this technology, which we believe to be superior to any known process for treating Covid-19 and any subsequent mutations of the disease. We believe we can, together with our research partners, quickly develop the necessary binding (complexing) agents to respond to mutations and variations as they present themselves."

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC Pink:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to several patent pending COVID-19 extracorporeal treatments:

Title

Application No.

Filing Date

Priority

Status

Method for Treating and Curing Covid-19 Infection

US 62/989981

03/16/2020

n/a

Provisional application Pending

Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients

US 63/007207

04/08/2020

n/a

Provisional application Pending

Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus

US 63/013104

4/21/2020

n/a

Provisional application Pending

Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 which cover the extracorporeal treatment of diseases.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

ReleaseID: 595524

Capstone Turbine (NASDAQ:CPST) Announces That in Fiscal 2020 It Saved End-Use Customers an Estimated $219 Million in Energy Costs and 368,000 Tons of Carbon

Capstone End-Use Customers' Total Energy Savings Approach an Estimated Half a Billion Dollars and 718,000 Tons of Carbon Over the Last Two Fiscal Years

VAN NUYS, CA / ACCESSWIRE / June 29, 2020 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world's leading clean technology manufacturer of microturbine energy systems, announced today its annual estimated end-use customer microturbine financial savings and environmental benefits.

During fiscal year 2020, Capstone Turbine saved end-use customers an estimated $219 million in annual energy costs and 368,000 tons of carbon. The fiscal 2020 results demonstrate continued progress in carbon savings, up 5% from the prior fiscal year, but were offset somewhat by cleaner electrical utility grids in the U.S. and Europe.

Total end-use customer energy savings dropped 13% compared to the prior fiscal year. This result is largely due to the decline in electricity rates as energy prices dropped in some key countries with significant fleets of Capstone combined heat and power (CHP) energy efficiency systems, which in turn has helped to drive the majority of the environmental and cost benefits. A single Capstone powered CHP system can provide customers an annual energy savings of an estimated 40% while simultaneously meaningfully lowering their carbon footprint.

Capstone is committed to saving customers money by improving the energy efficiency of its operations around the world. Microturbine based high-efficiency energy systems provide an economic benefit while also reducing carbon and global emissions in order to create a better environment and help end-use customers achieve their carbon reduction goals while also providing energy resiliency.

"The need to shift to greener energy solutions has never been more evident than it is today. In fact, there is a strong argument to be made for a green recovery from the COVID-19 pandemic, especially in Europe, as they are already moving ahead in this direction," said Darren Jamison, President and Chief Executive Officer of Capstone Turbine.

"This movement to lower emissions and promote higher efficiency energy solutions should not be a political issue that divides us, but a social issue that unites us all to improve the environment while simultaneously saving money and creating more green jobs. I believe businesses will increasingly begin to look at improving their operations from an environmental, social and governance (ESG) perspective so that they become more socially conscious, especially as investors and customers are beginning to screen companies closer for their stance on these issues before potentially investing or making product buying decisions," added Mr. Jamison.

"At Capstone, the products and services we produce enable our end-use customers to reduce their air emissions and lower their operational costs. We apply the same guiding principles to our internal processes at Capstone, focusing on reducing our own environmental footprint through waste reduction efforts, reducing energy consumption in our processes, and continuously monitoring and improving our overall carbon footprint," stated Kirk Petty, Capstone's Senior Vice President of Operations. "We also strive to foster a corporate culture of lean manufacturing that helps to provide our employees with a safe and productive work environment, even with the increased challenges associated with operating during the current global pandemic," concluded Mr. Petty.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) is the world's leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, via our direct sales team, as well as our global distribution network. Capstone provides scalable solutions from 30 kWs to 10 MWs that operate on a variety of fuels and are the ideal solution for today's multi-technology distributed power generation projects.

For customers with limited capital or short-term needs, Capstone offers rental systems, for more information, contact: rentals@capstoneturbine.com. To date, Capstone has shipped nearly 10,000 units to 83 countries and in FY20, saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, and YouTube.

Forward-Looking Statements

This press release contains "forward-looking statements," as that term is used in the federal securities laws. Forward-looking statements may be identified by words such as "expects," "believes," "objective," "intend," "targeted," "plan" and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone's filings with the Securities and Exchange Commission that may cause Capstone's actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

"Capstone" and "Capstone Microturbine" are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT: Capstone Turbine Corporation

Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

Integra Investor Relations
Shawn M. Severson
415-226-7747
cpst@integra-ir.com

SOURCE: Capstone Turbine Corporation

ReleaseID: 595535

Milestone Scientific Added to Russell 3000(R) and Russell Microcap(R) Indexes

ROSELAND, NJ / ACCESSWIRE / June 29, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has been added to the Russell 3000® and Russell Microcap® Indexes, following the annual Russell indexes reconstitution, effective after the market open on June 29, according to a final list of additions posted on June 26.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 8, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Leonard Osser, CEO of Milestone Scientific, stated, "We're pleased to be included in the Russell 3000® and Russell Microcap® Indexes. These additions reflect our continued progress as we move forward with the launch of our medical instruments based on our proprietary Dynamic Pressure Sensing technology®. We believe our inclusion in the Russell Indexes will help improve awareness, liquidity and exposure within the global community of institutional investors."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information on the Russell 3000® Index, Russell Microcap® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

About FTSE Russell

FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $16 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives. FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit www.ftserussell.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2019. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACT:

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

SOURCE: Milestone Scientific, Inc.

ReleaseID: 594973

Dyadic Joins Russell 2000(R) Index and Russell 3000(R) Index

JUPITER, FL / ACCESSWIRE / June 29, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced today that the Company will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index effective after the US market opens on June 29, as a result of the annual Russell index reconstitution.

"We are very pleased to join the Russell 2000 Index and Russell 3000 Index representing another significant company achievement. Our inclusion further highlights the ongoing growth in our business portfolio and the expansion of our visibility in the investment community as we continue to successfully demonstrate the broad application potential of our robust C1 technology platform," said Mark Emalfarb, Chief Executive Officer.

The Russell 3000® Index measures the performance of the largest 3,000 US companies representing approximately 98% of the investable US equity market. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell US Indexes primarily by objective, market-capitalization rankings and style attributes.

Russell US Indexes are widely used by investment managers and institutional investors for passive funds and investment products and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against the Russell US Indexes.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic's website at http://www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at http://www.dyadic.com.

Contact:

Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: prawson@dyadic.com

SOURCE: Dyadic International, Inc.

ReleaseID: 595513

Analysis of Coronavirus Impact: Nitrobenzene Manufacturers to Feel Impact of Pandemic Owing to Worker Shortages and Uncertainties in Capital Markets

Major manufacturers of nitrobenzene are setting up social distancing strategies in their facilities in addition to the optimization of supply chains, to bring back operational capabilities during the coronavirus crisis.

ROCKVILLE, MD / ACCESSWIRE / June 29, 2020 / The global nitrobenzene market is expected to grow 1.4x, at a moderate 3.6% CAGR, during the assessment period 2020 – 2030. The global nitrobenzene market has been hit hard owing to a number of factors during the covid-19 pandemic. Disruptions in end use verticals has reduced global demand. In addition, suspension of factory activities has impacted productivity. In addition, reluctance by investors, supply chain disruptions, and workforce shortages has also hurt market prospects in the short term.

According to the study released by Fact.MR, nitrobenzene manufacturers have to focus on evaluating budgets, cash flow, and supply chains during this low-revenue period. Temporary closure of facilities could threaten the survival of small-scale businesses in the industry.

"The nitrobenzene market is gaining opportunities owing to strong demand for nitrobenzene, which will replace chemicals that emit volatile organic compounds, meeting the needs of sustainability goals. Rapid developments in the dyes, pharmaceuticals, pesticide, and chemical industries will account for substantial market growth through the end of the pandemic," says the FACT.MR study.

Request a report sample to gain more market insights at-

https://www.factmr.com/connectus/sample?flag=S&rep_id=4733

Nitrobenzene Market- Critical Takeaways

Aniline manufacturing remains the primary application for nitrobenzene, driven by extensive usage in the rubber industry.
Pharmaceutical applications of nitrobenzene are gaining ground, propelled by use in paracetamol production.
Construction industry is a major consumer of nitrobenzene, owing to the demand for MDI products in residential and commercial projects.
Asia Pacific has emerged as a prominent nitrobenzene market, as major manufacturers are pushing their production facilities to the region.

Nitrobenzene Market- Drivers

Strong demand for aniline in construction and automotive industries support the adoption of nitrobenzene.
Extensive applications in agriculture, cosmetics, and industrial applications generate lucrative opportunities.
Rising production and use of polyurethane products help in the growth of the nitrobenzene market.
Cheaper raw material and low labor costs in the Chinese market boost the nitrobenzene market.

Nitrobenzene Market- Restraints

High demand for bio-based chemicals and regulations associated to environment protection hamper market growth.
Carcinogenic properties of nitrobenzene and health concerns hurt global adoption rates.

COVID-19 Impact on Nitrobenzene Market

Prior to the pandemic, the nitrobenzene market had been slammed by the U.S. – China trade war. With the pandemic spreading across the globe, the Chinese industry has been among the worst effected by the outbreak. Currently concerns over a second wave of coronavirus cases, are hampering developments in the nitrobenzene industry. International restrictions on exports and imports also affect the global market. Poor demand arising from a downturn in construction and automotive industrial activity will restrict the market. The recovery of the market post-pandemic will go well into 2021 as the automotive industry is expected to gain demand gradually in the months ahead.

Explore the global nitrobenzene market with 194 figures, 74 data tables, along with the table of contents of the report. You can also find detailed segmentation on

https://www.factmr.com/report/4733/nitrobenzene-market

Competitive Landscape

Prominent nitrobenzene manufacturers are investing in strategic mergers and acquisitions. Also, major producers pushing for the expansion of production capacities. For instance, Solvay has acquired U.S. based Cytec for composite materials and technology. Further, SABIC has merged with Aramco, which will contribute to its portfolio including that of nitrobenzene.

Huntsman Corporation, Wanhua Chemical Group Co. Ltd., BASF SE, and Covestro AG are some of the key nitrobenzene producers in the global market.

About the Study

The study offers readers an exhaustive market forecast of the nitrobenzene market. Global, regional and national-level analysis of the latest industry trends influencing the nitrobenzene market is covered in this FACT.MR report. The study provides actionable insights on nitrobenzene market according to application (aniline production, pesticide additive, synthetic rubber manufacturing, paint solvent, and others), and end use (construction, agriculture, pharmaceutical, automotive, and others) across six regions (North America, Latin America, Europe, South Asia & Oceania, East Asia, and MEA).

Explore Fact.MR's Coverage of the Global Chemical & Materials Industry

Advanced High Strength Steel (AHSS) Market– Get insights on the global advanced high strength steel market through FACT.MR's report covering detailed analysis for projection period (2020-2030).

Halogenated Solvent Cleaners Market– FACT.MR's study on the global halogenated solvent cleaners market covers new trends, tech advancements, key players, and strategies for the period 2018-2027.

Technical Aerosol Market– Obtain analysis on the global technical aerosol market through FACT.MR's report covering competitive analysis, key regions, and segmental analysis for 2018-2028.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FACT.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the chemical & materials sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR's latest market reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1488/global-nitrobenzene-market

SOURCE: FactMR

ReleaseID: 595574

Jerash Reports $0.57 GAAP EPS for Fiscal Year 2020

Revenue Increases 10%, Net Income Grows 27%

New Customers Account for 7% of Revenue

FAIRFIELD, NY / ACCESSWIRE / June 29, 2020 / Jerash Holdings (US), Inc. (NASDAQ:JRSH) (the "Company" or "Jerash"), a producer of high-quality textile goods for leading global brands, today reported results for its fiscal 2020 fourth quarter and full year, ended March 31, 2020.

Fiscal Year 2020 and Recent Highlights

Reported $93.0 million full-year revenue, an annual increase of 9.5% and a new record, driven by increased customer orders and the addition of new customers;
Generated full-year gross margin of 19.3%, reflecting the absorption of ramp-up costs for the acquired Paramount facility and the Al-Hasa sewing workshop, as well as the impact of a shutdown due to COVID-19 restrictions during the last two weeks of the fiscal year;
Reported GAAP net income of $6.5 million, or $0.57 per diluted share, an increase of 26.6% compared with net income of $5.1 million, or $0.45 per diluted share in the prior year;
Added multiple new customers in fiscal 2020 expected to increase their order volumes at Jerash in fiscal 2021; and
Ended the year with cash of $26.9 million and working capital of $48.1 million.

Fiscal Fourth Quarter 2020 Highlights

Reported $14.4 million fourth quarter revenue, effectively flat year over year, primarily due to approximately $1.6 million in shipments deferred to fiscal 2021 as a result of the Jordanian COVID-19 shutdowns in March 2020;
Generated quarterly gross margin of 8.7%, compared with 17.7% in the prior-year fourth quarter, reflecting the COVID-19 related halt to production and shipments during the last two weeks of the quarter and the addition of Al-Hasa start-up costs.

Management Commentary

Sam Choi, Chairman and Chief Executive Officer, stated: "Jerash posted a 9.5% increase in revenue in fiscal 2020 while onboarding more than 1.5 million pieces of new capacity that will be fully available for the first time in fiscal 2021. GAAP net income grew 26.6% to $0.57 per diluted share, and we paid out $0.20 per share in dividends over the course of the year.

"The global pandemic did impact our fiscal fourth quarter revenue and gross margin due to the closure of our factories on March 18 in compliance with a country-wide shelter-in-place order from the Jordanian government. We reopened on April 4 with our dormitory-housed workforce and deployed additional cleaning and hygiene protocols to ensure the safety of our workers. Since then, orders that were initially cancelled or deferred by customers early in the pandemic have been reinstated, which we believe reflects the value of our duty-free imports and high-quality production capabilities.

We expect fiscal 2021 to benefit from our investments during the past year to expand capacity, bring in new customers and diversify our product categories. With the 23% increase in annual production capacity from the Paramount acquisition, we are fully scaled to meet customer demand from both existing and new customers. We have also expanded our capabilities to include face masks and other medical garments and personal protective equipment requested by multiple parties. We look forward to the year ahead as we work to further expand our business in terms of both product type and client bases."

Fiscal 2020 Financial Results

For fiscal 2020, Jerash reported record total revenue of $93.0 million, an increase of $8.0 million, or 9.5%, from $85.0 million in fiscal 2019. The increase in full-year sales reflected increased utilization of the Company's manufacturing capacity in the second half of the fiscal year through the addition of new orders from both existing and new customers. The second half also saw initial revenue contribution from the launch of production at the acquired Paramount factory, which is expected to be a contributor to capacity expansion in fiscal 2021. Sales to new customers such as New Balance and G-III accounted for 7.2% of the fiscal 2020 revenue, with additional capacity demand from those new accounts and others anticipated in fiscal 2021.

Gross margin for fiscal 2020 was 19.3%, compared with 22.1% in fiscal 2019. Gross margin was reduced by approximately 110 basis points due to the factory shutdown toward the end of fiscal 2020. The two-week loss of production had a margin impact of approximately $985,000. The remainder of the year-over-year change in gross margin reflected increased utilization of existing factories, offset by the startup process for the acquired Paramount factory, which is expected to expand Jerash's annual production capacity by more than 23%, and the Al-Hasa workshop. Gross margin also reflected changes in product mix for the full year, due to the increase in sales during the second half of the fiscal year, which is characterized by warmer weather pieces as opposed to jackets and outwear with relatively higher gross margin, which have historically dominated the Company's production volume.

Operating expenses for fiscal 2020 were $10.3 million, a decline of 17.0% compared with $12.4 million in fiscal 2019. Operating expenses included additional headcount costs related to Paramount staffing and expansion in the Company's Asia-based sales and marketing and support teams to continue customer relationship growth, offset by a $3.3 million reduction in stock-based compensation expense.

Operating income for fiscal 2020 was $7.6 million, an increase of 20.0% from $6.4 million in fiscal 2019.

GAAP net income for fiscal 2020 was $6.5 million, or $0.57 per diluted share, an increase of 26.6% compared with net income of $5.1 million, or $0.45 per diluted share in fiscal 2019.

"Jerash's full-year results demonstrate our ability to scale the business and drive net income even as we worked to expand capacity and position Jerash for future growth," said Gilbert Lee, Chief Financial Officer. "We believe that our investments in capacity expansion and customer diversification will provide long-term value to our stockholders. The COVID-19 pandemic and resulting business shutdowns mandated by the Jordanian government beginning in March delayed certain shipments into the first quarter of fiscal 2021, and we anticipate some volatility in orders due to customer adjustments in their supply chain ahead. We have already seen most of the deferred or cancelled orders reinstated as key countries re-open, and will continue to work hard to maximize our business opportunities ahead."

Fiscal Fourth Quarter 2020 Financial Results

Jerash reported revenue of $14.4 million for the fiscal fourth quarter ended March 31, 2020, compared with $14.5 million in the prior-year fourth quarter. Revenue reflected growth in customer demand for warmer season goods, offset by the cessation of shipments starting from March 18, 2020 due to the COVID-19 pandemic. As a result, approximately $1.6 million in fourth quarter orders were deferred into the first quarter of fiscal 2021. This closure and deferral also impacted gross margin in the fiscal fourth quarter. Operating expenses were $2.0 million for the fiscal fourth quarter, down 28.4% from $2.8 million in the prior-year fourth quarter. For the quarter, Jerash reported a GAAP net loss of $741,000, or $0.07 per share, compared to net loss of $215,000, or $0.02 per share, in the prior year fourth quarter. The shut down during the last two weeks of the quarter due to COVID-19 increased the net loss by approximately $985,000, or $0.09 per diluted share.

COVID-19 Update

Jerash was impacted in the fourth quarter of fiscal 2020 and first quarter of fiscal 2021 by business closure mandates across the country of Jordan beginning March 18. As a result of the shutdown, shipments were delayed and production at the factories halted until the government approved re-opening. Jerash's dormitory workforce was allowed to resume production within the industrial zone on April 4, followed by local employees returning on June 1. Concurrently, Jerash enacted a number of additional screening, cleaning and monitoring programs designed to protect the health and well-being of its workforce. The Company also continued to pay its workers their salaries during the closure. Jerash has been recognized as a model employer by the country of Jordan for its efforts, and no cases of COVID-19 were reported among its Jordanian employees.

Subsequent to re-opening, Jerash is working closely with its customers to adjust orders and meet revised customer demand, while also addressing its capabilities as a reliable strategic garment manufacturing option outside of China to both existing and prospective customers.

Additionally, Jerash has commenced shipments of both branded and disposable face masks to a new customer following the re-opening, and is currently exploring opportunities for production of additional categories of personal protective equipment for customers, including medical scrubs and surgical gowns.

Balance Sheet, Cash Flow and Dividends

Cash and restricted cash at March 31, 2020 was $26.9 million, inventory was $22.6 million, primarily comprised of fabric, work in progress and finished garments, and accounts receivable were $5.3 million. Working capital was $48.1 million as of March 31, 2020.

Jerash approved payment of a regular quarterly dividend of 5 cents per share on the Company's common stock on or about June 2, 2020, to shareholders of record on May 26, 2020.

During fiscal 2020, the Company invested $2.3 million into the purchases of the Paramount manufacturing assets and land properties to further expand its production facilities and worker dormitories as part of its multi-year facilities expansion plan.

Conference Call

The Company will conduct a conference call and webcast to review its fiscal 2020 results on Monday, June 29, 2020, at 9:00 a.m. ET. Interested parties can access the call by dialing +1-862-298-0850. Callers should dial in at least 5 minutes prior to the call start time. A live and archived webcast will be available online in the investor relations section of Jerash's website at www.jerashholdings.com.

About Jerash Holdings (US), Inc.

Jerash Holdings (US), Inc. (Nasdaq:JRSH) is a manufacturer utilized by many well-known brands and retailers, such as Walmart, Costco, Hanes, New Balance, G-III, VF Corporation (which owns brands such as The North Face, Timberland, JanSport, etc.), and PVH Corp. (which owns brands such as Calvin Klein, Tommy Hilfiger, IZOD, etc.). Its production facilities comprise four factory units, one workshop, and three warehouses and it currently employs approximately 4,100 people. The total annual capacity at its facilities was approximately 8.0 million pieces as of March 31, 2020. Additional information is available at www.jerashholdings.com.

Forward Looking Statements

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect", "seek", "potential," "outlook" and similar expressions are intended to identify forward-looking statements. Such statements reflect Jerash's current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made, including those risks described from time to time in filings made by Jerash with the Securities and Exchange Commission. In addition, there is uncertainty about the continuous spread of the COVID-19 virus and the impact it may have on the Company's operations, the demand for the Company's products, global supply chains and economic activity in general. These and other risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. Statements contained in this news release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Jerash does not intend and does not assume any obligation to update these forward-looking statements, other than as required by law.

Contact:

Matt Kreps, Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

JERASH HOLDINGS (US), INC.,
SUBSIDIARIES AND AFFILIATE
CONSOLIDATED BALANCE SHEETS

 

 
March 31,
 

 

 
2020
 
 
2019
 

 

 
 
 
 
 
 

ASSETS

 
 
 
 
 
 

Current Assets:

 
 
 
 
 
 

Cash

 
$
26,130,411
 
 
$
27,182,158
 

Accounts receivable, net

 
 
5,335,748
 
 
 
4,020,369
 

Inventories

 
 
22,633,772
 
 
 
21,074,243
 

Prepaid expenses and other current assets

 
 
2,761,877
 
 
 
2,630,727
 

Advance to suppliers, net

 
 
2,116,367
 
 
 
443,395
 

Total Current Assets

 
 
58,978,175
 
 
 
55,350,892
 

 

 
 
 
 
 
 
 
 

Restricted cash

 
 
786,298
 
 
 
652,310
 

Long-term deposits

 
 
253,414
 
 
 
810,172
 

Deferred tax assets, net

 
 
139,895
 
 
 
81,461
 

Property, plant and equipment, net

 
 
6,174,164
 
 
 
2,356,262
 

Right of use assets

 
 
1,147,090
 
 
 

 

Total Assets

 
$
67,479,036
 
 
$
59,251,097
 

 

 
 
 
 
 
 
 
 

LIABILITIES AND EQUITY

 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 

Current Liabilities:

 
 
 
 
 
 
 
 

Credit facilities

 
$
235
 
 
$
648,711
 

Accounts payable

 
 
6,376,320
 
 
 
3,378,258
 

Accrued expenses

 
 
2,245,402
 
 
 
1,539,147
 

Income tax payable – current

 
 
1,088,497
 
 
 
1,164,238
 

Other payables

 
 
929,783
 
 
 
855,527
 

Operating lease liabilities – current

 
 
210,081
 
 
 

 

Total Current Liabilities

 
 
10,850,318
 
 
 
7,585,881
 

 

 
 
 
 
 
 
 
 

Operating lease liabilities – non-current

 
 
649,935
 
 
 

 

Income tax payable – non-current

 
 
1,227,632
 
 
 
1,403,087
 

Total Liabilities

 
 
12,727,885
 
 
 
8,988,968
 

 

 
 
 
 
 
 
 
 

Commitments and Contingencies (See Note 15)

 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 

Equity

 
 
 
 
 
 
 
 

Preferred stock, $0.001 par value; 500,000 shares authorized; none issued and outstanding

 
$

 
 
$

 

Common stock, $0.001 par value; 30,000,000 shares authorized; 11,325,000 shares issued and outstanding

 
 
11,325
 
 
 
11,325
 

Additional paid-in capital

 
 
15,235,025
 
 
 
14,956,767
 

Statutory reserve

 
 
212,739
 
 
 
212,739
 

Retained earnings

 
 
38,997,177
 
 
 
34,786,735
 

Accumulated other comprehensive loss

 
 
(8,324
)
 
 
(14,440
)

Total Jerash Holdings (US), Inc.'s Stockholder's Equity

 
 
54,447,942
 
 
 
49,953,126
 

 

 
 
 
 
 
 
 
 

Noncontrolling interest

 
 
303,209
 
 
 
309,003
 

Total Equity

 
 
54,751,151
 
 
 
50,262,129
 

 

 
 
 
 
 
 
 
 

Total Liabilities and Equity

 
$
67,479,036
 
 
$
59,251,097
 

JERASH HOLDINGS (US), INC.,
SUBSIDIARIES AND AFFILIATE
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

 

 
For the Years Ended
March 31,
 

 

 
2020
 
 
2019
 

 

 
 
 
 
 
 

Revenue, net

 
$
93,024,236
 
 
$
84,983,661
 

Cost of goods sold

 
 
75,040,597
 
 
 
66,206,652
 

Gross Profit

 
 
17,983,639
 
 
 
18,777,009
 

 

 
 
 
 
 
 
 
 

Selling, general and administrative expenses

 
 
10,039,995
 
 
 
8,834,547
 

Stock-based compensation expenses

 
 
278,258
 
 
 
3,593,888
 

Total Operating Expenses

 
 
10,318,253
 
 
 
12,428,435
 

 

 
 
 
 
 
 
 
 

Income from Operations

 
 
7,665,386
 
 
 
6,348,574
 

 

 
 
 
 
 
 
 
 

Other (Expense) Income:

 
 
 
 
 
 
 
 

Other (expense) income, net

 
 
(21,120
)
 
 
23,802
 

Total other (expense) income, net

 
 
(21,120
)
 
 
23,802
 

 

 
 
 
 
 
 
 
 

Net Income before provision for income taxes

 
 
7,644,266
 
 
 
6,372,376
 

 

 
 
 
 
 
 
 
 

Income tax expense

 
 
1,174,618
 
 
 
1,260,861
 

 

 
 
 
 
 
 
 
 

Net Income

 
 
6,469,648
 
 
 
5,111,515
 

 

 
 
 
 
 
 
 
 

Net loss attributable to noncontrolling interest

 
 
5,794
 
 
 
754
 

Net income attributable to Jerash Holdings (US), Inc.'s

 
 
 
 
 
 
 
 

Common Stockholders

 
$
6,475,442
 
 
$
5,112,269
 

 

 
 
 
 
 
 
 
 

Net Income

 
$
6,469,648
 
 
$
5,111,515
 

Other Comprehensive Income:

 
 
 
 
 
 
 
 

Foreign currency translation gain

 
 
6,116
 
 
 
10,215
 

Total Comprehensive Income

 
 
6,475,764
 
 
 
5,121,730
 

Comprehensive loss attributable to noncontrolling interest

 
 

 
 
 
601
 

Comprehensive Income Attributable to Jerash Holdings (US), Inc.'s Common Stockholders

 
$
6,475,764
 
 
$
5,122,331
 

 

 
 
 
 
 
 
 
 

Earnings Per Share Attributable to Common Stockholders:

 
 
 
 
 
 
 
 

Basic

 
$
0.57
 
 
$
0.46
 

Diluted

 
$
0.57
 
 
$
0.45
 

 

 
 
 
 
 
 
 
 

Weighted Average Number of Shares

 
 
 
 
 
 
 
 

Basic

 
 
11,325,000
 
 
 
11,199,630
 

Diluted

 
 
11,443,364
 
 
 
11,330,310
 

 

 
 
 
 
 
 
 
 

Dividend per share

 
$
0.20
 
 
$
0.10
 

JERASH HOLDINGS (US), INC.,
SUBSIDIARIES AND AFFILIATE
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

 

 
For the Quarters Ended
March 31,
 

 

 
2020
 
 
2019
 

 

 
 
 
 
 
 

Revenue, net

 

14,439.084
 
 

14,479,015
 

Cost of goods sold

 
 
13,184,325
 
 
 
11,910,408
 

Gross Profit

 
 
1,254,759
 
 
 
2,568,607
 

 

 
 
 
 
 
 
 
 

Selling, general and administrative expenses

 
 
1,905,734
 
 
 
2,584,443
 

Stock-based compensation expenses

 
 
84,303
 
 
 
193,954
 

Total Operating Expenses

 
 
1,990,037
 
 
 
2,778,397
 

 

 
 
 
 
 
 
 
 

(Loss) from Operations

 
 
(735,278
)
 
 
(209,790
)

 

 
 
 
 
 
 
 
 

Other (Expense) Income:

 
 
 
 
 
 
 
 

Other (expense) income, net

 
 
(17,441
)
 
 
4,169
 

Total other (expense) income, net

 
 
(17,441
)
 
 
4,169
 

 

 
 
 
 
 
 
 
 

Net (loss) before provision for income taxes

 
 
(752,719
)
 
 
(205,621
)

 

 
 
 
 
 
 
 
 

Income tax expense

 
 
(10,874
)
 
 
9,861
 

 

 
 
 
 
 
 
 
 

Net (Loss)

 
 
(741,845
)
 
 
(215,482
)

 

 
 
 
 
 
 
 
 

Net loss attributable to noncontrolling interest

 
 
1,783
 
 
 
8
 

Net (loss) attributable to Jerash Holdings (US), Inc.'s

 
 
 
 
 
 
 
 

Common Stockholders

 

(740,062
)
 

(215,474
)

 

 
 
 
 
 
 
 
 

Net (Loss)

 

(741,845
)
 

(215,482
)

Other Comprehensive Income:

 
 
 
 
 
 
 
 

Foreign currency translation gain

 
 
1,664
 
 
 
124
 

Total Comprehensive (Loss)

 
 
(740,181
)
 
 
(215,358
)

Comprehensive loss attributable to noncontrolling interest

 
 

 
 
 
9
 

Comprehensive (Loss) Attributable to Jerash Holdings (US), Inc.'s Common Stockholders

 

(740,181
)
 

(215,349
)

 

 
 
 
 
 
 
 
 

Earnings Per Share Attributable to Common Stockholders:

 
 
 
 
 
 
 
 

Basic

 

(0.07
)
 

(0.02
)

Diluted

 

(0.07
)
 

(0.02
)

 

 
 
 
 
 
 
 
 

Weighted Average Number of Shares

 
 
 
 
 
 
 
 

Basic

 
 
11,325,000
 
 
 
11,325,000
 

Diluted

 
 
11,325,000
 
 
 
11,325,000
 

 

 
 
 
 
 
 
 
 

Dividend per share

 

0.05
 
 

0.05
 

SOURCE: Jerash Holdings (US), Inc.

ReleaseID: 595512

9 Meters Biopharma, Inc. Amends Definition of Primary Endpoint for Phase 3 Trial in Celiac Disease After Consultation with FDA

-New methodology enables a more capital-efficient study, with reduction in participants from 630 to 525 while maintaining statistical powering at 90%

-Continuous variable approach more aptly reflects change in celiac disease patient symptoms over trial duration

RALEIGH, NC / ACCESSWIRE / June 29, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that, after consultation with the FDA, the company will modify its definition of the primary endpoint in the ongoing Phase 3 trial evaluating larazotide for treating celiac disease. The validated instrument used for the primary assessment remains the Celiac Disease Patient-Reported Outcome (CeD PRO). However, the definition of the primary endpoint will now utilize a continuous variable instead of a responder analysis. The design and execution of the ongoing trial have not been affected.

The trial is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of larazotide for patients with celiac disease who continue to experience gastrointestinal symptoms while following a gluten-free diet. The primary efficacy outcome of the study comprises the mean change from baseline on the CeD PRO rating scale abdominal domain over 12 weeks for two active treatment doses (0.25 mg and 0.50 mg) compared to placebo.

"We have adjusted our approach to the primary endpoint calculation after consultation with the FDA to utilize a continuous variable instead of a responder analysis. Consequently, we have reduced the size of the study population to 525 from the original 630, while maintaining the study's original 90% statistical powering," said Patrick H. Griffin, M.D., FACP, chief medical officer of 9 Meters.

The trial is currently under way at over 100 clinical sites, with an interim analysis still anticipated during the first half of 2021 and topline data anticipated in the second half of 2021. For more information on the trial, please visit Clinicaltrials.gov: NCT03569007.

About 9 Meters Biopharma

9 Meters Biopharma, Inc. ("the Company") is a rare unmet needs-focused GI platform company. The Company is advancing NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for Short Bowel Syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease.

For more information, please visit www.9meters.com.

Forward-looking Statements

This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, the potential effects of the ongoing coronavirus outbreak and related mitigation efforts on the Company's clinical, financial and operational activities; the Company's continued listing on Nasdaq; expectations regarding future financings; the future operations of the Company; the nature, strategy and focus of the Company; the development and commercial potential and potential benefits of any product candidates of the Company; anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical and preclinical results; the Company having sufficient resources to advance its pipeline; and any other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) uncertainties associated with the clinical development and regulatory approval of product candidates; (ii) risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) the impact of COVID-19 on our operations, clinical trials or proposed merger and future financings and (vi) risks associated with the possible failure to realize certain anticipated benefits of the Company's recent merger and the Naia acquisition, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's. Annual Report on Form 10-K for the year ended December 31, 2019, Form 10-Q for the quarter ended March 31, 2020 and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Corporate contacts

Edward J. Sitar
Chief Financial Officer
9 Meters Biopharma, Inc.
investor-relations@9meters.com
www.9meters.com

Media contact

Amy Jobe, Ph.D.
LifeSci Communications, LLC
ajobe@lifescicomms.com
315-879-8192

Investor contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

SOURCE: 9 Meters Biopharma, Inc.

ReleaseID: 595392

More Than Just a Money-Making Venture: Trinhoval Business Strategies

Most companies today have a shared, and similar goal – to make a substantial profit. But for some people, like California native and entrepreneur David Verity, running a business is more than just managing a money-making venture.

NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Most companies today have a shared, and similar goal – to make a substantial profit. But for some people, like California native and entrepreneur David Verity, running a business is more than just managing a money-making venture.

Being raised poor and on the wrong side of town in Modesto, California, David did not have all the typical experience of being a child. There were no sidewalks to walk on, and numerous gang members tagged fences in his neighborhood, known as "The Varrio," from the word barrio, roughly meaning "ghetto" in Spanish. When his parents got divorced and he moved to a better neighborhood with his mother, one would assume that David's quality of life improved. Unfortunately, it did not. The divorce subsequently brought him to live with an abusive stepfather who made his life worse.

Although David was a Straight-A student, he was kicked out of school because of the sleep disorder he suffered from having a bad home. He was then homeschooled, and that was when he found his love for music.

By the time he was 16 years old, he was the #1 r&b artist on an online music platform called MP3.com. Because of his great talent as a musician, producer, singer, and songwriter, he sold numerous albums around the world and was eventually ranked number one on Billboard's Top Online Independent Talent Chart. His successes continued to flourish while he finished homeschool. By then, he was given the option to either participate in his graduation ceremony or perform live at the world's Mecca of Entertainment – the MGM Grand in Las Vegas, Nevada.

As any motivated and aspiring artist would do, David chose the latter.

However, when his sister's battle with addiction threatened to separate their family, David and his mom decided to take in his sister's children. This brought David's momentum to a halt. He took care of them while his mother burnt the midnight oil to earn enough money for the family. But by the time his sister's children moved out, that was when he decided to reshape his career – from being a top R&B artist to an entrepreneur with a purpose. Helping others.

Because of his dream to contribute as much to the world by making it a better place, he decided to help the disadvantaged to have more in life. That is why, by creating Trinhoval Business Strategies, David made sure that his company would put people first over profits.

Trinhoval Business Strategies is a digital marketing agency that aims to close the gap between small businesses and big corporations with high-level marketing strategies through the use of proprietary technology. In other words, the company allows local businesses to achieve the same level of quality branding from more internationally-renowned brands.

Because David often felt being the "little guy" when he was younger and a newbie in the industry, he shaped his company to root for small business owners to thrive and survive in this dog-eat-dog world. He knew what it felt to have no one to turn to. That is why he dedicated his company to focus more on those who are a bit disadvantaged, regardless of how much David and Trinhoval Business Strategies would make.

Many small businesses don't have an advocate when it comes to their success. They're just everyday citizens with families and dreams. Which, due to his ability to relate to that position, is exactly why David advocates for them.

Learn more about David Verity and Trinhoval Business Strategies by visiting their website and following David's Instagram page. You can also send an email to pr@trinhoval.com or call (855) 874-6468 for more information.

SOURCE: Authority Titans

ReleaseID: 595712